Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

RMJ. 2018; 43(4): 661-664


Role of Coenzyme Q10 in pre-eclamptic patients

Farheen Shaikh, Tazeen Shah, Ayaz Memon, Muhammad Yousuf Memon, Ghulam Chanihoon.




Abstract

Objective: To analyze CoQ10 supplements during pregnancy and reduced the risk of pre-eclampsia in women as compared with normal healthy women
Methodolgy:This case control, comparative study was conducted in department of Biochemistry, Liaquat University of Medical & Health Sciences (LUMHS), Jamshoro from February 2015 to October 2015 and patients were recruited from department of Obstetrics & Gynaecology of the hospitlal. A total 100 volunteers were recruited and divided into two groups; 50 were normotensive healthy pregnant women as a control group and 50 were patients with pre-eclampsia as experimental group. They were recruited based on sign and symptoms, obstetric history, anthropometric, clinical data. Blood samples were analysed for CoQ10 by High performance liquid chromatography (HPLC) with Diode Array Detector (DAD).
Results: The plasma CoQ10 level before supplementation was found to be decreased in pre-eclamptic patients (0.22±0.09) μg/dl as compared with control group (1.08±0.36) μg/dl. After 3 months of supplementation of CoQ10, plasma levels of CoQ10 increased significantly (p

Key words: Pre-eclampsia, Co-Enzyme Q10, High liquid chromatography.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.